Back to News
Market Impact: 0.05
EURETINA: PulseSight Therapeutics to Present Results of Phase 1 clinical trial of PST-611 treatment for dry AMD/Geographic Atrophy (GA)
Source: GlobeNewswire
Healthcare & Biotech
The article only states that a late-breaking oral presentation is scheduled for the 26th EURETINA Congress in Vienna from 1-4 October 2026. It provides no clinical data, company details, financial metrics, or market-moving information.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Premarket movers: Intel jumps on SK Hynix memory-chip talks, J.B. Hunt slides
- Japan has a problematic age gap: 100,000-plus residents are over 100 and the pension system is buckling
- The MLB and its Dominican pipeline is selling false promises and shady contracts to children as young as 11
- Arrowhead Pharmaceuticals at H.C. Wainwright: launch and pipeline widen
- A healthcare provider is set up for a big move higher, according to the charts
- The Download: AI’s trillion-dollar gamble and OpenAI’s biology data bid